scorecardresearch
Wednesday, Oct 05, 2022
Premium

Covaxin neutralises double mutant strain of SARS-CoV-2: ICMR study

ICMR scientists have said that the NIV has demonstrated the neutralization potential of Covaxin against the UK variant and Brazil variant.

covaxin, coronavirus vaccine, Haffkine Pharmaceutical, india news, indian expressCovaxin has been manufactured by Hyderabad-based Bharat Biotech. (File)

Covid-19 vaccine Covaxin, which is made by Bharat Biotech, has been found to effectively neutralise the double mutant strain, B.1.617, of SARS-CoV-2 and other variants, the Indian Council of Medical Research (ICMR) has said.

Dr Samiran Panda, chief of epidemiology and communicable diseases division of ICMR, said it is good news and hoped that there will be less anxiety among people in the second wave with this new information about the vaccine. Covaxin has been found to effectively neutralise the double mutant strain also apart from other variants of concern, Dr Panda said.

At ICMR-National Institute of Virology, scientists said they have isolated and cultured the double mutant strain which has E484Q and L452R mutations. They have also isolated and cultured all variants of concern of SARS-CoV-2 virus: B.1.1.7 (UK variant); B.1.1.28.2 (Brazil variant) and B.1.351 (South African variant), the scientists said.

– Stay updated with the latest Pune news. Follow Express Pune on Twitter here and on Facebook here. You can also join our Express Pune Telegram channel here.

Subscriber Only Stories
Telangana plot accused had twice tried to join terror outfits abroad, sto...Premium
Split on method to name new Supreme Court judges, CJI sends 2nd note to C...Premium
MNREGA worker breaks national record in men’s 35km race walkPremium
Over-reach, will stay out, Election Commission told Supreme Court before ...Premium

ICMR scientists said the NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variant. The data for the South African variant is being generated. Recently, ICMR-NIV successfully isolated and cultured the double mutant strain B.1.617 (E484Q and L452R) prevalent in certain regions of India.

Bharat Biotech also tweeted that with the accelerated Phase 3 vaccination schedule starting on May 1, it is essential to know the answers to vaccine efficacy and listed details in their blog.

First published on: 21-04-2021 at 01:18:34 pm
Next Story

Thailand: Third COVID wave threatens plans to reopen tourism

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement